International Journal of Medicinal Mushrooms, Vol. 9, pp. 7–14 (2007)
Evaluation of Therapeutic Activity of Hypogeous
Ascomycetes and Basidiomycetes from North America
Rita Stanikunaite,1 James M. Trappe,2 Shabana I. Khan,3
and Samir A. Ross1,3
1
Department of Pharmacognosy, The University of Mississippi, University, MS, USA; 2Department of Forest
Science, Oregon State University, Corvallis, OR, USA; 3National Center for Natural Products Research, The
University of Mississippi, University, MS, USA
Address all correspondence to Samir A. Ross, National Center for Natural Products Research, PO Box 1848, University, MS 38677,
USA; Tel.: 662-915-1031; Fax: 662-915-7989; sross@olemiss.edu
ABSTRACT: This study is the first broad investigation of therapeutic activities of hypogeous truffles
and truffle-like fungi (Ascomycetes and Basidiomycetes) from North America. Twenty-two species
from 12 families were evaluated in several biological assays for antimicrobial, antimalarial, antiinflammatory, antioxidant, antituberculosis, and anticancer activities. Biological screening results indicate that 1 species showed antimalarial activity, 11 species were active in antioxidant assay, 9 species
were active in antiinflammatory assay, 9 species showed antituberculosis activity, and 2 species
showed anticancer activity. Among the screened species, Elaphomyces granulatus, E. muricatus,
Geopora clausa, Hymenogaster subalpinus, Melanogaster tuberiformis, Rhizopogon couchii,
R. nigrescens, R. pedicellus, R. subaustralis, R. subgelatinosus, and Scleroderma laeve expressed
therapeutic activity in more than one assay. Our results indicate that this group of fungi has promising
therapeutic activities that could lead to the development of new agents for the treatment and prevention
of diseases.
KEY WORDS: Ascomycetes and Basidiomycetes fungi, hypogeous fungi, therapeutic activities,
antimicrobial, antimalarial, antituberculosis, anticancer, antiinflammatory, antioxidant
INTRODUCTION
Fungi-producing hypogeous (underground) fruiting
bodies occur over a wide range of orders in the
Ascomycetes and Basidiomycetes (Castellano et al.,
2004; Claridge and Trappe, 2005; Trappe and
Claridge, 2005). This fruiting habit likely evolved
from natural selection pressure to better withstand
unfavorable environmental conditions, such as
drought and frost, than their above-ground mushroom ancestors (Percudani et al., 1999; Trappe and
Claridge, 2005). Ascomycetes, commonly termed
ABBREVIATIONS
COX-2: cyclooxygenase-2; DCF: 2′,7′-dichlorodihydrofluorescein; DCFH-DA: 2′,7′-dichlorodihydrofluorescein
diacetate; DMSO: dimethyl sulfoxide; DPPH: 2,2-diphenyl-1-picrylhydrazyl radical; LPS: lipopolysaccharide;
MIC: minimum inhibitory concentration; PMA: phorbol 12-myristate 13 acetate; SRB: sulforhodamine B; TCA:
trichloroacetic acid.
1521-9437/07/$35.00
© 2007 by Begell House, Inc.
Begell House Inc., http://begellhouse.com Downloaded 2008-2-23 from IP 76.221.184.227 by Rita Stanikunaite (rstanikunaite)
7
R. STANIKUNAITE ET AL.
true truffles, occur in orders Pezizales (including
families Discinaceae, Helvellaceae, Pezizaceae, Pyronemataceae, and Tuberaceae) and Eurotiales (family
Elaphomycetaceae) (Trappe, 1979; Castellano et al.,
2004). Species belonging to the higher Basidiomycetes
are usually referred to as false truffles, or truffle-like
fungi, and occur in various orders and families, such
as Cortinariaceae, Boletaceae, Leucogastraceae,
Rhizopogonaceae, among others (Castellano et al.,
1989, 2004).
Hypogeous fruiting bodies are produced by the
mycelium of fungi that form ectomycorrhizae with
a variety of gymnosperms and angiosperms
(Trappe, 1971; Trappe and Claridge, 2005). These
fruiting bodies are rounded to irregular in shape,
mostly 1–10 cm in diameter. They produce spores,
usually internally, that remain enclosed inside the
fruiting body, which matures underground (Trappe
and Claridge, 2005). As spores mature, the fruiting
bodies emit aromatic substances that attract animals, which unearth and eat them (mycophagy).
The animals digest the fruiting body tissues, but the
spores pass through the digestive tract unharmed
and are then dispersed through defecation. Each
species produces its own combination of aromatics—humans may perceive these as pleasantly
pungent, garlicky, cheesy, fruity, sweet, etc, which
is the reason some species have high culinary
values. However, the odors of many species are
regarded as unpleasant to most human observers,
although evidently not to other animals (Trappe
and Claridge, 2005).
Truffles have been used as a culinary delicacy
for thousands of years and were known to the ancient
Egypt, Greek, and Roman civilizations. In Europe,
Tuber melanosporum (Perigord black truffle) and
Tuber magnatum (Italian white truffle) are the most
highly valued, both gastronomically and economically. Truffles have been used fresh and unprocessed
as a condiment in cooking, in making liqueurs, for
scenting tobacco, and in the perfume industry (Gao
et al., 2001). They are rich in proteins, amino acids,
vitamins, and minerals, such as phosphorus and
potassium (Ashour-Ahmed et al., 1981; Claridge and
Trappe, 2005). Research on the chemical composition of truffles has revealed alcohols, aldehydes,
ethers, ketones, and sulphur compounds forming
8
truffle aromatic constituents (Talou et al., 1987; Diaz
et al., 2002). Research on the chemistry and medicinal properties of truffles has been limited to a few
species of Terfezia, Tirmania, and Tuber from
Europe, North America, and Asia (Marin et al., 1984;
Marin and McDaniel, 1987; Chellal and Lukasova,
1995; Lanzotti and Iorizzi, 2000; Gao et al., 2004;
Janakat et al., 2005; Shaker, 2005).
The goal of this study was to investigate the
therapeutic activity of hypogeous fungi from North
America as a potential source of bioactive compounds that could contribute to the development of
new drugs. Twenty-two species were screened in
biological assays for antimicrobial, antimalarial, antioxidant, antiinflammatory, antituberculosis, and
anticancer activities.
MATERIALS AND METHODS
Collection
Fruiting bodies of hypogeous fungi from Ascomycetes
and Basidiomycetes were collected by members of
the North American Truffling Society and identified
by Dr. James M. Trappe. Voucher specimens have
been deposited in the Mycological Herbarium,
Department of Botany and Plant Pathology, Oregon
State University, USA (Table 1). Astraeus pteridis
is not a truffle-like species in the strict sense, but its
early stages develop underground much of the same
as truffles, and it emerges only at maturity.
Extract Preparation
The fruiting bodies of fungal specimens were dried
for 24 hours in a forced air dehydrator at 35°C. Five
grams of the dried, powdered material of each fungal
species were separately extracted with an ASE 200
Accelerated Solvent Extractor (Dionex, Sunnyvale,
CA, USA) by the following procedure: extracted 3
times with 95% EtOH at 40°C, then extracted 2 times
with 70% EtOH at 40°C. The 95% EtOH extract was
concentrated under reduced pressure to yield residue
A; the 70% EtOH extract was concentrated under
reduced pressure to yield residue B.
International Journal of Medicinal Mushrooms
Begell House Inc., http://begellhouse.com Downloaded 2008-2-23 from IP 76.221.184.227 by Rita Stanikunaite (rstanikunaite)
EVALUATION OF THERAPEUTIC ACTIVITY OF HYPOGEOUS ASCOMYCETES AND BASIDIOMYCETES FROM NORTH AMERICA
Table 1. Screened Fungus Species
OSC
accession no.
Class
Family
Species
Ascomycetes
Elaphomycetaceae
Elaphomyces granulatus Fr.
Elaphomyces muricatus Fr.
20881
12300
Bonner County, Idaho
Benton County, Oregon
Helvellaceae
Barssia oregonensis Gilkey
27997
Clackamas County, Oregon
Pyronemataceae
Geopora clausa Tul. et C. Tul.
Boletaceae
Gastroboletus subalpinus Trappe et Thiers
Truncocolumella citrina Zeller
27882
22967
Douglas County, Oregon
Clackamas County, Oregon
Cortinariaceae
Hymenogaster subalpinus A. H. Sm.
Thaxterogaster pingue (Zeller) Singer et A. H. Sm.
27992
23395
Benton County, Oregon
Linn County, Oregon
6004
Benton County, Oregon
Basidiomycetes
5715
Collection location
Inyo County, California
Gautieriaceae
Gautieria monticola Harkn.
Leucogastraceae
Leucogaster rubescens Zeller et C. W. Dodge
23589
Pend Oreille County, Idaho
Melanogastraceae
Melanogaster tuberiformis Corda
27998
Lane County, Oregon
Rhizopogonaceae
Rhizopogon
Rhizopogon
Rhizopogon
Rhizopogon
Rhizopogon
Rhizopogon
Rhizopogon
27933
25707
27932
25562
23132
27931
7108
Lebanon State Forest, New Jersey
Clearwater County, Idaho
Lebanon State Forest, New Jersey
Pend Oreille County, Idaho
Lewis County, Washington
Lebanon State Forest, New Jersey
Jackson County, Oregon
Sedeculaceae
Sedecula pulvinata Zeller
19197
Valley County, Idaho
Sclerodermataceae
Astraeus pteridis (Shear) Zeller
Scleroderma laeve Lloyd
27893
27936
Linn County, Oregon
Lebanon State Forest, New Jersey
Tricholomataceae
Hydnangium carneum Wallr.
couchii A. H. Sm.
idahoensis A. H. Sm.
nigrescens Coker et Couch
pedicellus A. H. Sm.
subareolatus A. H. Sm.
subaustralis A. H. Sm.
subgelatinosus A. H. Sm.
Evaluation of Biological Activity
Antimicrobial assay. All organisms were obtained
from the American Type Culture Collection (ATCC)
and included the fungi Candida albicans ATCC
90028, Cryptococcus neoformans ATCC 90113,
and Aspergillus fumigatus ATCC 90906 and the
bacteria Staphylococcus aureus ATCC 29213,
methicillin-resistant S. aureus ATCC 43300 (MRS),
Pseudomonas aeruginosa ATCC 27853, and Mycobacterium intracellulare ATCC 23068. Susceptibility testing was performed by a modified version of
the NCCLS methods (NCCLS, 1997, 1998,
2000a,b). M. intracellulare was tested by a modified method of Franzblau et al. (1998). Briefly,
samples (dissolved in DMSO) were serially diluted
with 0.9% saline and transferred in duplicate to 96well microplates. Inocula were prepared by diluting
8842
Humboldt County, California
microbe suspensions with assay media (Sabouraud
Dextrose [Difco, www.fishersci.com] for C. albicans
and C. neoformans, cation-adjusted Mueller-Hinton
[Difco] for Staphylococcus, YM broth [Difco, buffered with 0.165M MOPS at pH 7.3] for A. fumigatus,
and 5% Alamar Blue [BioSource International,
Camarillo, CA, USA] in Middlebrook 7H9 broth with
OADC enrichment, pH = 7.3 for M. intracellulare)
to afford the desired colony forming units/mL at
turbidimetric readings of 630 nm. The microbial
inocula were added to the samples to achieve a final
volume of 200 µL and final sample concentration of
200 µg/mL. Growth (saline only), solvent, and blank
(media only) controls were included on each test
plate. Drug controls (Ciprofloxacin [ICN Biomedicals,
Warrendale, PA, USA] for bacteria and Amphotericin B [ICN Biomedicals] for fungi) were included in
each assay. Except for A. fumigatus, which was
Volume 9, Issue 1, 2007
Begell House Inc., http://begellhouse.com Downloaded 2008-2-23 from IP 76.221.184.227 by Rita Stanikunaite (rstanikunaite)
9
R. STANIKUNAITE ET AL.
inspected visually, all other organisms were read at
either 630 nm with the EL-340 Biokinetics Reader
(Bio-Tek Instruments, Winooski, VT, USA) or 544ex/
590em, gain = 25 (M. intracellulare) with the Polarstar
Galaxy Plate Reader (BMG LabTechnologies, Bottco,
Germany) prior to and after incubation: C. albicans,
S. aureus, and P. aeruginosa at 37°C for 18–24
hours, C. neoformans and A. fumigatus at 30°C for
72 hours, and M. intracellulare at 37°C and 10% CO2
for 72 hours.
Antimalarial assay. The assay is based on the
determination of plasmodial LDH activity. For the
assay, a suspension of red blood cells infected with
D6 or W2 strains of Plasmodium falciparum (200 µL,
with 2% parasitemia and 2% hematocrit in RPMI
1640 medium supplemented with 10% human serum
and 60 µg/mL amikacin) was added to the wells of
a 96-well plate containing 10 µL test samples diluted
in medium at various concentrations. The plate was
placed in a modular incubation chamber (BillupsRothenberg, Del Mar, CA, USA) and flushed with a
gas mixture of 90% N2, 5% O2, and 5% CO2 and
incubated at 37°C for 72 hours. Parasitic LDH
activity was determined by use of MalstatTM reagent
(Flow Inc., Portland, OR, USA) according to the
procedure of Makler and Hinrichs (1993). Briefly,
20 µL of the incubation mixture was mixed with
100 µL of the MalstatTM reagent and incubated at
room temperature for 30 minutes. Twenty microliters of a 1:1 mixture of NBT/PES (Sigma Aldrich,
www.Sigma-Aldrich.com) was then added, and the
plate was further stopped by the addition of 100 µL
of a 5% acetic acid solution. The plate was read at
650 nm with the EL-340 Biokinetics Reader (BioTek Instruments). IC50 values were computed from
the dose response curves. Artemisinin and chloroquine were included in each assay as the drug controls. DMSO (0.25%) was used as vehicle control.
Antiinflammatory assay. The assay is based
on the determination of COX-2 activity. Mouse
macrophages (RAW 264.7, ATCC) were cultured
in 75 cm2 culture flask in RPMI-1640 medium
(GibcoTM, Carlsbad, CA, USA; Invitrogen Corp.,
Carlsbad, CA, USA) supplemented with 10% bovine calf serum (Hyclone, Logan, UT, USA) and
60 mg/L amikacin (Sigma) at 37°C in an environment of 95% humidity and 5% CO2. For the assay,
10
cells were seeded in the wells of 96-well plates
(50,000 cells/well) and incubated at 37°C for 24
hours. After washing with RPMI-1640 medium
supplemented with 3% bovine calf serum, they
were then incubated with 5 µg/mL lipopolysaccharide (LPS) (Escherichia coli 055:B5, Sigma) for 16
hours to induce the production of COX-2. Induced
cells were washed thoroughly with medium to remove LPS completely and treated with different
concentrations of test samples (extracts or pure
samples) for 2 hours. Arachidonic acid (300 µM,
Sigma) was added, and the cells were further incubated for 30 minutes. The amount of PGE2 released
in the medium was determined with the PGE2
Enzyme Immunoassay kit (Cayman Chemical Co.,
Ann Arbor, MI, USA). COX-2 activity was determined by the conversion of exogenous arachidonic
acid to PGE2, expressed as percentage of the vehicle
control. The concentration that caused 50% inhibition of enzyme activity (IC50) was calculated from
the dose curves generated by plotting % COX-2
activity against the test concentrations. NS-0398
(Cayman), a specific inhibitor of COX-2, was included as a positive control in each assay.
Assay for antioxidant activity. Myelomonocytic HL-60 cells (ATCC) were grown in RPMI
1640 medium supplemented with 10% fetal bovine
serum (Hyclone) and 60 mg/mL amikacin at 37°C
in an environment of 95% humidity and 5% CO2.
For the assay, 125 µL of the cell suspension (1 × 106
cells/mL) was added to the wells of a 96-well plate.
After treating with different concentrations of the
test samples for 30 minutes, the cells were stimulated with 100 ng/mL phorbol 12-myristate 13acetate (PMA, Sigma) for 30 minutes. DCFH-DA
(Molecular Probe, Carlsbad, CA, USA; 5 µg/mL) is
added, and the cells were incubated for 15 minutes.
The levels of DCF produced were measured on a
PolarStar plate reader with an excitation wavelength
at 485 nm and emission at 530 nm, as described
previously (Takamatsu et al., 2003; Choi, et al.,
2006). The ability of the test materials to inhibit
exogenous cytoplasmic ROS-catalysed oxidation of
DCFH to fluorescent DCF in HL-60 cells was measured in comparison to PMA-treated controls without the test materials. IC50 values were calculated
from dose curves of % DCF production versus test
International Journal of Medicinal Mushrooms
Begell House Inc., http://begellhouse.com Downloaded 2008-2-23 from IP 76.221.184.227 by Rita Stanikunaite (rstanikunaite)
EVALUATION OF THERAPEUTIC ACTIVITY OF HYPOGEOUS ASCOMYCETES AND BASIDIOMYCETES FROM NORTH AMERICA
concentrations. Vitamin C (Sigma) was included as
a positive control.
Antituberculosis assay. The antituberculosis
activity was determined against M. tuberculosis H37Rv
(ATCC 27294) in the Microplate Alamar Blue assay
(Collins and Franzblau, 1997). The minimum inhibitory concentration (MIC) was defined as the lowest
concentration affecting a reduction in fluorescence of
90% relative to controls. Rifampin was included as
a positive quality control compound for each test
with expected MIC ranges of 0.06–0.125 µg/mL.
Anticancer assay. A colorimetric assay that
uses sulforhodamine B (SRB) reaction has been
adapted for a quantitative measurement of cell growth
and viability (Skehan et al., 1990). This form of the
assay employs 96-well cell culture microplates of
9 mm diameter (Mosmann, 1983; Faircloth et al.,
1988). Most of the cell lines were obtained from
ATCC derived from different human cancer types.
Tested cell lines included HT-29 (colon carcinoma),
A549 (lung carcinoma), LOVO-DOX (colon carcinoma), and SK-MEL-28 (malignant melanoma). Cells
were maintained in RPMI 1640 10% FBS, supplemented with 0.1 g/L penicillin and 0.1 g/L streptomycin sulfate, and then incubated at 37ºC, 5% CO2, and
98% humidity. For the experiments, cells were harvested from subconfluent cultures with trypsin and
resuspended in fresh medium before plating. Cells
were seeded in 96-well microtiter plates at 5 × 103
cells per well in aliquots of 195 µL medium, and they
were allowed to attach to the plate surface by growing in drug-free medium for 18 hours. Afterward,
samples were in aliquots of 5 µL in a range of 10 to
10–8 µg/mL dissolved in DMSO/EtOH (0.2% in PS
buffer). After 48 hours’ exposure, the antitumor
effect was measured by the SRB methodology: cells
were fixed by adding 50 µL of cold 50% (wt/vol)
trichloroacetic acid (TCA) and incubating for 60
minutes at 4ºC. Plates were washed with deionized
water and dried. One hundred µL of SRB solution
(0.4% wt/vol in 1% acetic acid) was added to each
microtiter well and incubated for 10 minutes at room
temperature. Unbound SRB was removed by washing with 1% acetic acid. Plates were air-dried, and
bound stain was solubilized with Tris buffer. Optical
densities were read on an automated spectrophotometric plate reader at a single wavelength of 490 nm.
RESULTS AND DISCUSSION
Twenty two species from 12 families, representing
both the Ascomycetes and Basidiomycetes, were
evaluated in this study (Table 1).
Crude mushroom extracts were evaluated in several biological assays for antimicrobial, antimalarial,
antiinflammatory, antioxidant, antituberculosis, and
anticancer activities. Biological screening results indicate that 1 species showed weak antimalarial activity,
11 species exhibited moderate to weak antioxidant
activity, 9 species showed significant antiinflammatory
activity, 9 species were active in antituberculosis assay,
and 2 species showed weak anticancer activity in the
in vitro cell-based assays (Table 2). Elaphomyces
granulatus, E. muricatus, Geopora clausa, Hymenogaster subalpinus, Melanogaster tuberiformis, Rhizopogon couchii, R. nigrescens, R. pedicellus,
R. subaustralis, R. subgelatinosus, and Scleroderma
laeve expressed biological activity in more than 1 assay.
This study is the first broad investigation of
therapeutic activities of hypogeous Ascomycetes and
Basidiomycetes fungi from North America. Our results indicate that this group of fungi has promising
biological activities that could lead to the development of new agents for the treatment and prevention
of diseases.
ACKNOWLEDGMENTS
We thank Thad Cochran, National Center for Natural
Products Research, University of Mississippi, for antimicrobial, antimalarial assays supported by the NIH,
NIAID, Division of AIDS, Grant No. AI 27094. Part
of the study was supported by the USDA Agricultural
Research Service Specific Cooperative Agreement
No. 58-6408-2-0009. We also thank Ms. Sh. Moktan
for help with the antioxidant assay, PharmaMar for the
anticancer assay, and University of Illinois at Chicago
for the antituberculosis assay. Dr. M. Castellano and
members of the North American Truffling Society,
especially A. Beyerle, S. Hopkins, M. Hinds, and
M. Weber, devoted enthusiastic effort to collecting
specimens in the field. J. M. Trappe’s participation in
the study was supported in part by the US Forest
Service, Pacific Northwest Research Station.
Volume 9, Issue 1, 2007
Begell House Inc., http://begellhouse.com Downloaded 2008-2-23 from IP 76.221.184.227 by Rita Stanikunaite (rstanikunaite)
11
R. STANIKUNAITE ET AL.
Table 2. Therapeutic Activity of Screened Species
Therapeutic activity
Species
Astraeus pteridis
Barssia oregonensis
Elaphomyces granulatus
Elaphomyces muricatus
Gastroboletus subalpinus
Gautieria monticola
Geopora clausa
Hydnangium carneum
Hymenogaster subalpinus
Leucogaster rubescens
Melanogaster tuberiformis
Rhizopogon couchii
Rhizopogon idahoensis
Rhizopogon nigrescens
Rhizopogon pedicellus
Rhizopogon subareolatus
Rhizopogon subaustralis
Rhizopogon subgelatinosus
Scleroderma laeve
Sedecula pulvinata
Thaxterogaster pingue
Truncocolumella citrina
a
Extract
AMI
AMA b
AOc
AId
ATe
AC f
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
A
B
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
WA
WA
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
WA
WA
–
WA
–
–
–
WA
–
MA
–
–
–
–
MA
–
WA
WA
MA
WA
–
–
WA
–
–
MA
–
–
WA
–
–
–
SA
WA
–
–
–
–
–
–
–
–
–
–
SA
SA
A
–
–
–
–
–
–
–
–
–
A
A
–
–
A
A
A
A
–
–
SA
SA
–
–
–
–
A
A
A
A
SA
A
–
–
–
–
–
–
SA
MA
MA
MA
SA
–
WA
–
–
–
–
–
–
–
–
–
SA
–
–
–
SA
–
MA
–
–
–
–
–
WA
–
–
–
–
–
–
–
SA
WA
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
WA
WA
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
–
WA
–
–
–
–
–
–
–
–
–
Note: – = not active, A = active, WA = weakly active, MA = moderately active, SA = strongly
active; AMI = antimicrobial assay, AMA = antimalarial assay, AO = antioxidant assay, AI =
antiinflammatory assay, AT= antituberculosis assay, AC = anticancer assay.
a A: 95% EtOH extract, B: 70% EtOH extract.
b WA: samples showing % inhibition > 50 at 15.9 µg/mL in primary assay and IC ≥ 40,000 ng/mL
50
in secondary assay.
c SA: samples showing IC < 20 µg/mL; MA: IC 20–50 µg/mL; WA: IC > 50 µg/mL.
50
50
50
d SA: samples showing % inhibition of COX-2 > 60% at 50 µg/mL; A: 45–60% at 50 µg/mL.
e SA: samples showing IC < 20 µg/mL; MA: IC 20–50 µg/mL; WA: IC > 50 µg/mL.
50
50
50
f WA: based on the proposed scale by PharmaMar.
12
International Journal of Medicinal Mushrooms
Begell House Inc., http://begellhouse.com Downloaded 2008-2-23 from IP 76.221.184.227 by Rita Stanikunaite (rstanikunaite)
EVALUATION OF THERAPEUTIC ACTIVITY OF HYPOGEOUS ASCOMYCETES AND BASIDIOMYCETES FROM NORTH AMERICA
REFERENCES
Ashour-Ahmed A., Mohamed M. A., and Hami M. A.
1981. Lybian truffles Terfezia boudieri Chatin:
chemical composition and toxicity. J Food Sci,
46, 927–929.
Castellano M. A., Trappe J. M., and Luoma D. L.
2004. Sequestrate fungi. In: Biodiversity of Fungi:
Inventory and Monitoring Methods, Mueller G.
M., Bills G. F., and Foster M. S., eds., Elsevier
Academic Press, Burlington, MA; San Diego, CA;
London, UK, pp. 197–213.
Castellano M. A., Trappe J. M., Maser Z., and
Maser C. 1989. Key to Spores of the Genera of
Hypogeous Fungi of North Temperate Forests with
Special Reference to Animal Mycophagy. Mad
River Press, Eureka, California.
Chellal A. and Lukasova E. 1995. Evidence for antibiotics in the two Algerian truffles Terfezia and
Tirmania. Pharmazie, 50, 228–229.
Choi Y. W., Takamatsu S., Khan S. I., Srinivas P. V.,
Ferreira D., Zhao J., and Khan I. A. 2006.
Schisandrene, a dibenzocyclooctadiene lignan from
Schisandra chinensis: structure-antioxidant activity relationships of dibenzocyclooctadiene lignans.
J Nat Prod, 69, 356–359.
Claridge A. W. and Trappe J. M. 2005. Sporocarp
mycophagy: nutritional, behavioral, evolutionary
and physiological aspects. In: The Fungal Community. Dighton J., Oudemans P. and White J., eds.
CRC Press, Boca Raton, FL, pp. 599–611.
Collins L. and Franzblau S. G. 1997. Microplate alamar
blue assay versus BACTEC 460 system for highthroughput screening of compounds against Mycobacterium tuberculosis and Mycobacterium avium.
Antimicrob Agents Chemother, 41, 1004–1009.
Diaz P., Senorans F. J., Reglero G., and Ibanez E.
2002. Truffle aroma analysis by headspace solid
phase microextraction. J Agric Food Chem, 50,
6468–6472.
Faircloth G. T., Stewart D., and Clement J. J. 1988.
A simple screening procedure for the quantitative
measurement of cytotoxicity assay. J Tissue Culture Methods, 11, 201–205.
Franzblau S. G., Witzig R. S., McLauhlin J. C., Torres
P., Madico G., Hernandez A., Degnan M. T., Cook
M. B., Quenzer V. K., Ferguson R. M., and Gilman
R. H. 1998. Rapid low-technology MIC determination with clinical Mycobacterium tuberculosis iso-
lates by using the microplate Alamar Blue assay.
J Clin Microbiol, 36, 362–366.
Gao J. M., Wang C. Y., Zhang A. L., and Liu J. K.
2001. A new trihydroxy fatty acid from the ascomycete, Chinese truffle Tuber indicum. Lipids,
36, 1365–1370.
Gao J. M., Zhu W. M., Zhang S. Q., Zhang X., Zhang
A. L., Chen H., Sun Y. Y., and Tang M. 2004.
Sphingolipids from the edible fungus Tuber
indicum. Eur J Lipid Technol, 106, 815–821.
Janakat S. M., Al-Fakhiri S. M., and Sallal A. K. J.
2005. Evaluation of antibacterial activity of aqueous and methanolic extracts of the truffle Terfezia
claveryi against Pseudomonas aeruginosa. Saudi
Med J, 26, 952–955.
Lanzotti V. and Iorizzi M. 2000. Chemical constituents of tubers. The case of Tuber borchii Vitt.
Proc Phytochem Soc Eur, 46, pp. 37–43.
Makler M. T. and Hinrichs D. J. 1993. Measurement
of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia.
Am J Trop Med Hyg, 48, 205–210.
Marin A. B., Libbey L. B., and Morgan M. F. 1984.
Truffles: on the scent of buried treasure. McIlvainea,
6, 34–38.
Marin A. B. and McDaniel M. R. 1987. An examination of hedonic response to Tuber gibbosum and
three other native Oregon truffles. J Food Sci, 52,
1305–1307.
Mosmann T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods,
65, 55–63.
NCCLS. 1997. Reference method for broth dilution
antifungal susceptibility testing of yeasts; approved
standard M27-A. National Committee on Clinical
Laboratory Standards, 17, 9.
NCCLS. 1998. Reference method for broth dilution
antifungal susceptibility testing of conidium-forming filamentous fungi; proposed standard M38-P.
National Committee on Clinical Laboratory Standards, 18, 13.
NCCLS. 2000a. Methods for dilution antimicrobial
susceptibility tests for bacteria that grow aerobically M7-A5. National Committee on Clinical
Laboratory Standards, 20, 2.
NCCLS. 2000b. Susceptibility testing of Mycobac-
Volume 9, Issue 1, 2007
Begell House Inc., http://begellhouse.com Downloaded 2008-2-23 from IP 76.221.184.227 by Rita Stanikunaite (rstanikunaite)
13
R. STANIKUNAITE ET AL.
teria, Nocardia and other aerobic Actinomycetes;
tentative standard, 2nd edition, M24-T2. National
Committee on Clinical Laboratory Standards,
20, 26.
Percudani R., Trevisi A., Zambonelli A., and
Ottonello S. 1999. Molecular phylogeny of truffles
(Pezizales: Terfeziaceae, Tuberaceae) derived from
nuclear rDNA sequence analysis. Mol Phylogen
Evol, 13, 169–180.
Shaker E. S. 2005. Biological studies and antioxidative
activity for white truffle fungus (Tuber borchii).
Special Publication, Royal Society of Chemistry,
300 (Food Flavor and Chemistry), 312–322.
Skehan P., Storeng R., Scudiero D., Monks A.,
McMahon J., Vistica D., Warren J., Bokesch
H. T., Kenney S., and Boyd M. R. 1990. New
colorimetric cytotoxicity assay for anticancer drug
screening. J Nat Cancer Inst, 82, 1107–1112.
Takamatsu S., Galal A. M., Ross S. A., Ferreira D.,
Elsohly M. A., Ibrahim A. R., and El-Feraly
F. S. 2003. Antioxidant effect of flavanoids on
14
DCF production in HL-60 cells. Phytother Res,
17, 963–966.
Talou T., Delmas M., and Gaset A. 1987. Principal
constituents of Black Truffle (Tuber melanosporum)
aroma. J Agricult Food Chem, 35, 774–777.
Trappe J. M. 1971. Mycorrhiza-forming Ascomycetes.
In: Mycorrhizae, Proceedings of the 1st North American Conference on Mycorrhizae. Hacskaylo E., ed.
USDA Forest Service Miscellaneous Publication
1189, Washington, DC, pp. 19–37.
Trappe J. M. 1979. The orders, families and genera of
hypogeous Ascomycotina. Mycotaxon, 9, 297–340.
Trappe J. and Castellano M. A. 1991. Keys to the
genera of truffles (Ascomycetes). McIlvainea, 10,
47–65.
Trappe J. and Claridge A. W. 2005. Hypogeous fungi:
evolution of reproductive and dispersal strategies
through interactions with animals and mycorrhizal
plants. In: The Fungal Community. Dighton J.,
Oudemans P., and White J., eds., CRC Press, Boca
Raton, FL, pp. 613–623.
International Journal of Medicinal Mushrooms
Begell House Inc., http://begellhouse.com Downloaded 2008-2-23 from IP 76.221.184.227 by Rita Stanikunaite (rstanikunaite)